Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-3001 in Women With Overactive Bladder
NCT00685113Phase 3Completed
- Sponsor
- Duramed Research
- Start
- May 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of oxybutynin in overactive bladder (OAB) (3 arms), sponsored by Duramed Research. Primary endpoint: Change in total weekly number of incontinence (urge and stress) episodes at 12 weeks. Started May 2008; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00685113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685113.